ArticleSignal transduction and targeted therapy2025
Epidemiological and phylogenetic characteristics of human metapneumovirus in Beijing, China, 2014-2024.
Article in Signal transduction and targeted therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Twenty-five years of human metapneumovirus research.Clinical microbiology reviews · 2026Review
- Epidemiological Characteristics and Evolutionary Characterization of Human Metapneumovirus in Jiaxing, China.Viruses · 2026Article
- Epidemiological and Molecular Characterization of Human Metapneumovirus (HMPV) in Children Under 14 Years of Age in Shijiazhuang City, China.Pathogens (Basel, Switzerland) · 2026Article
- Epidemiology, Genomic Diversity, and Evolutionary Dynamics of Human Metapneumovirus Over 7 Years of Integrated Community- and Hospital-Based Sentinel Surveillance in Senegal, 2018-2024.Influenza and other respiratory viruses · 2026Article
- Characteristics and Risk Factors Associated With Hospitalization and Severe Disease in Patients Aged ≥ 60 Years With Human Metapneumovirus Infection Over Three Consecutive Seasons (2021-2024) in Valladolid, Spain. The VALLAVIRUS Study.Influenza and other respiratory viruses · 2026Article
- Epidemiological characterization and phylogenetic analysis of human metapneumovirus isolated from children in Ningbo, China, 2020-2024.Microbial genomics · 2026Article
- Human Metapneumovirus (HMPV): Advances in Diagnosis, Molecular Epidemiology, and Clinical Impact of an Underrecognized Respiratory Virus.Diagnostics (Basel, Switzerland) · 2026Review
- Avian Metapneumovirus: Virology, Epidemiology, and Insights from a Comparative Analysis with Human Metapneumovirus-A Review.Biomolecules · 2026Review
- Molecular Evolution of theMicroorganisms · 2026Article
- Article
- Genomic evidence of HMPV resurgence in Beijing: Clade B2 triggers the 2024 winter epidemic peak.Virologica Sinica · 2026Article
- Genetic and epidemiological characteristics of the spread of human metapneumovirus in Bulgaria, 2023-2025.Frontiers in public health · 2026Article
- Gut microbiota and serum metabolome in children with human metapneumovirus infection.Frontiers in immunology · 2026Article
- Clinical characteristics, co-detection patterns and prognostic risk factors of human metapneumovirus infection in children: a retrospective study.Frontiers in cellular and infection microbiology · 2026Article
- Genotype turnover and global evolutionary dynamics of G gene duplication variants in human metapneumovirus: insights from prospective surveillance in Nantong, China, 2024-2025.Frontiers in microbiology · 2026Article
- Internalization-related host factors of common respiratory viruses.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
In November 2024, there was an unusual surge in human metapneumovirus (hMPV) infection cases in Beijing. We performed an epidemiological investigation among cases with acute respiratory tract infection (ARTI). We enrolled ARTI cases from 35 sentinel hospitals, collected samples and medical records, conducted comprehensive pathogen testing, sequenced target genes or whole genomes, and performed phylogenetic analysis. A total of 79,793 cases were included in this study from 2014 to 2024. The hMPV epidemic exhibited typical seasonality from December to April of the following year, with an overall positivity rate of hMPV of 1.6%. The positivity rate of hMPV was highest in the 0-4 year age group (3.4%) and remained relatively high (1.2%) among populations over 60 years of age. Genotypes A and B were cocirculated, with predominant genotypes alternating every two years. We identified two variants of A2c with 180 or 111 nucleotide duplications in the G gene since 2016, and the A2c
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.